Logo image of OLMA

OLEMA PHARMACEUTICALS INC (OLMA) Stock Fundamental Analysis

NASDAQ:OLMA - Nasdaq - US68062P1066 - Common Stock - Currency: USD

4.97  -0.02 (-0.4%)

Fundamental Rating

3

OLMA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While OLMA has a great health rating, there are worries on its profitability. OLMA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OLMA had negative earnings in the past year.
In the past year OLMA has reported a negative cash flow from operations.
In the past 5 years OLMA always reported negative net income.
In the past 5 years OLMA always reported negative operating cash flow.
OLMA Yearly Net Income VS EBIT VS OCF VS FCFOLMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

OLMA has a Return On Assets of -53.30%. This is comparable to the rest of the industry: OLMA outperforms 45.28% of its industry peers.
The Return On Equity of OLMA (-61.68%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -53.3%
ROE -61.68%
ROIC N/A
ROA(3y)-35.84%
ROA(5y)-886.91%
ROE(3y)-38.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OLMA Yearly ROA, ROE, ROICOLMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

OLMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OLMA Yearly Profit, Operating, Gross MarginsOLMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, OLMA has more shares outstanding
The number of shares outstanding for OLMA has been increased compared to 5 years ago.
There is no outstanding debt for OLMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OLMA Yearly Shares OutstandingOLMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OLMA Yearly Total Debt VS Total AssetsOLMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 3.13 indicates that OLMA is not in any danger for bankruptcy at the moment.
The Altman-Z score of OLMA (3.13) is better than 75.22% of its industry peers.
There is no outstanding debt for OLMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.13
ROIC/WACCN/A
WACCN/A
OLMA Yearly LT Debt VS Equity VS FCFOLMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

OLMA has a Current Ratio of 7.10. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.10, OLMA is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
A Quick Ratio of 7.10 indicates that OLMA has no problem at all paying its short term obligations.
OLMA's Quick ratio of 7.10 is fine compared to the rest of the industry. OLMA outperforms 68.09% of its industry peers.
Industry RankSector Rank
Current Ratio 7.1
Quick Ratio 7.1
OLMA Yearly Current Assets VS Current LiabilitesOLMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.60% over the past year.
EPS 1Y (TTM)5.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OLMA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.78%
EPS Next 2Y-12.4%
EPS Next 3Y-14.81%
EPS Next 5Y-9.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OLMA Yearly Revenue VS EstimatesOLMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
OLMA Yearly EPS VS EstimatesOLMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OLMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OLMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OLMA Price Earnings VS Forward Price EarningsOLMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OLMA Per share dataOLMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as OLMA's earnings are expected to decrease with -14.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.4%
EPS Next 3Y-14.81%

More info and screens

0

5. Dividend

5.1 Amount

OLMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OLEMA PHARMACEUTICALS INC

NASDAQ:OLMA (2/24/2025, 2:52:46 PM)

4.97

-0.02 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners103.39%
Inst Owner Change-95.1%
Ins Owners4.07%
Ins Owner Change-58.79%
Market Cap339.60M
Analysts85.71
Price Target29.92 (502.01%)
Short Float %12.83%
Short Ratio6.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.33%
Min EPS beat(2)-1.8%
Max EPS beat(2)4.46%
EPS beat(4)2
Avg EPS beat(4)0.55%
Min EPS beat(4)-1.8%
Max EPS beat(4)4.46%
EPS beat(8)5
Avg EPS beat(8)5.36%
EPS beat(12)7
Avg EPS beat(12)3.18%
EPS beat(16)8
Avg EPS beat(16)-11.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.76%
PT rev (3m)5.3%
EPS NQ rev (1m)2.91%
EPS NQ rev (3m)2.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0
BVpS2.91
TBVpS2.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.3%
ROE -61.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.84%
ROA(5y)-886.91%
ROE(3y)-38.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.1
Quick Ratio 7.1
Altman-Z 3.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)362.5%
Cap/Depr(5y)337.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-10.78%
EPS Next 2Y-12.4%
EPS Next 3Y-14.81%
EPS Next 5Y-9.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.76%
EBIT Next 3Y-29.96%
EBIT Next 5YN/A
FCF growth 1Y-18.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.26%
OCF growth 3YN/A
OCF growth 5YN/A